CANTON, Mass., Sept. 13 /PRNewswire-FirstCall/ -- Avitar, Inc. (OTC Bulletin Board: - ), developer of the world's first rapid, on-site, oral fluid-based screening test for drugs-of-abuse, has been selected to participate in the European Driving Under the Influence of Drugs (DRUID) Project.
"Avitar is pleased to be asked to participate in this important project, which is being conducted under the direction of the European Traffic Police Organization (TISPOL)," commented Pete Phildius, Avitar's Chairman and CEO. "As with workplace random drug testing in the United States, point-of-care (POC) oral fluid-based technology is being recognized as a key element in addressing the growing international drugged driving problem."
Frost & Sullivan, a leading market research and business consulting firm, notes that the POC drug testing market in Europe is set for rapid growth. Non-invasive POC technology, specifically oral fluid-based devices, in combination with applications such as road-side drug testing, is anticipated to be the catalyst for growth. By 2009, 33% of all drugs of abuse tests (DATs) will be performed on the POC format. (Source: European Drugs of Abuse Testing, Frost & Sullivan, 2006).
Under the DRUID project, oral fluid screening devices will be tested under operational police conditions by police forces in Germany, Spain, Italy, Belgium, Denmark, and Finland.
Avitar, Inc. develops, manufactures and markets innovative and proprietary products. Their field includes the oral fluid diagnostic market, the disease and clinical testing market, and customized polyurethane applications used in the wound dressing industry. Avitar manufactures ORALscreen®, the world's first non-invasive, rapid, onsite oral fluid test for drugs-of-abuse, as well as HYDRASORB®, an absorbent topical dressing for moderate to heavy exudating wounds. Avitar is also developing diagnostic strategies for disease and clinical testing in the estimated $25 billion in-vitro diagnostics market. Conditions targeted include influenza, diabetes, and pregnancy. For more information, see Avitar's website at https://avitarinc.com.
Safe Harbor Statement
This release contains forward looking statements that are subject to risks and uncertainties including the development and marketing of new applications and other risks that are detailed from time to time in the Company's filings with the Securities and Exchange Commission. In view of such risks and uncertainties, the Company's actual results could differ materially from those anticipated in such forward looking statements.
Jay C. Leatherman
The Investor Relations Group
Erika Moran / Tom Caden,
Lynn Granito / Susan Morgenbesser,